1993 related articles for article (PubMed ID: 3095946)
1. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
2. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
3. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Collen D; Stassen JM; De Cock F
Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
[TBL] [Abstract][Full Text] [Related]
5. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
Fry ET; Mack DL; Sobel BE
Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
7. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
Lourenço DM; Dosne AM; Kher A; Samama M
Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
[TBL] [Abstract][Full Text] [Related]
8. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
9. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
10. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
11. Role of alpha 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma.
Declerck PJ; Lijnen HR; Verstreken M; Collen D
Thromb Haemost; 1991 Apr; 65(4):394-8. PubMed ID: 2057921
[TBL] [Abstract][Full Text] [Related]
12. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
14. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin.
Abercrombie DM; Buchinski B; Salvato KA; Vovis GF; Stump DC; Broeze RJ
Thromb Haemost; 1990 Nov; 64(3):426-32. PubMed ID: 2128973
[TBL] [Abstract][Full Text] [Related]
15. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
Aisina RB; Moukhametova LI; Varfolomeyev SD
Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
[TBL] [Abstract][Full Text] [Related]
16. Fibrin-specific thrombolytic agents.
Collen D
Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
[TBL] [Abstract][Full Text] [Related]
17. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
Lijnen HR; De Wreede K; Demarsin E; Collen D
Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
[TBL] [Abstract][Full Text] [Related]
18. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
Stump DC; Stassen JM; Demarsin E; Collen D
Blood; 1987 Feb; 69(2):592-6. PubMed ID: 3099862
[TBL] [Abstract][Full Text] [Related]
19. [New thrombolytic agents].
Nguyen G; Samama M
Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of single chain forms of urokinase-type plasminogen activator.
Stump DC; Kieckens L; De Cock F; Collen D
J Pharmacol Exp Ther; 1987 Jul; 242(1):245-50. PubMed ID: 3612530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]